Brief: Richter says exchange rate adjusted revenue and profit growth expected at 15-20% this year
BUDAPEST, Aug 4 (Reuters) - Richter Gedeon Vegyeszeti
Gyar Nyrt GDRB.BU:
RICHTER SAYS THEIR BEST ESTIMATE IS 15-20% GROWTH BOTH IN
PROFITABILITY AND RATE ADJUSTED REVENUE
50% GROWTH IN VRAYLAR BIPOLAR TREATMENT DRUG SALES MAKES
FIRST FORECAST OF 10% GROWTH OBSOLETE
H1 GROWTH IS UNSURPASSABLE DUE TO BASE-EFFECT
(Reporting by Boldizsar Gyori)
((Boldizsar.Gyori@thomsonreuters.com;))
Recent news on Gedeon Richter
See all newsBrief: Hungary's Richter says US FDA accepted for review its new drug application for Fylrevy
Brief: Hungary's Richter Upgrades 2026 Pharma Clean EBIT Guidance To Double-Digit Growth
development partnership in Tirzepatide
AI in Hungary could unlock productivity gains of €15 billion, McKinsey says
Brief: Hungary's Richter and Hetero announce cooperation for development of semaglutide injection